Cargando…
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484402/ https://www.ncbi.nlm.nih.gov/pubmed/34550541 http://dx.doi.org/10.1007/s13555-021-00615-8 |
| _version_ | 1784577310908743680 |
|---|---|
| author | Geng, Bob Hebert, Adelaide A. Takiya, Liza Miller, Lauren Werth, John L. Zang, Chuanbo Sanders, Paul Lebwohl, Mark G. |
| author_facet | Geng, Bob Hebert, Adelaide A. Takiya, Liza Miller, Lauren Werth, John L. Zang, Chuanbo Sanders, Paul Lebwohl, Mark G. |
| author_sort | Geng, Bob |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8484402 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84844022021-10-08 Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis Geng, Bob Hebert, Adelaide A. Takiya, Liza Miller, Lauren Werth, John L. Zang, Chuanbo Sanders, Paul Lebwohl, Mark G. Dermatol Ther (Heidelb) Correction Springer Healthcare 2021-09-22 /pmc/articles/PMC8484402/ /pubmed/34550541 http://dx.doi.org/10.1007/s13555-021-00615-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Geng, Bob Hebert, Adelaide A. Takiya, Liza Miller, Lauren Werth, John L. Zang, Chuanbo Sanders, Paul Lebwohl, Mark G. Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis |
| title | Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis |
| title_full | Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis |
| title_fullStr | Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis |
| title_full_unstemmed | Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis |
| title_short | Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis |
| title_sort | correction to: efficacy and safety trends with continuous, long-term crisaborole use in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484402/ https://www.ncbi.nlm.nih.gov/pubmed/34550541 http://dx.doi.org/10.1007/s13555-021-00615-8 |
| work_keys_str_mv | AT gengbob correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT hebertadelaidea correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT takiyaliza correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT millerlauren correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT werthjohnl correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT zangchuanbo correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT sanderspaul correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis AT lebwohlmarkg correctiontoefficacyandsafetytrendswithcontinuouslongtermcrisaboroleuseinpatientsaged2yearswithmildtomoderateatopicdermatitis |